Drug Trial Radar · NCT03158948
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock
Last checked: Nov 19, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Jul 3, 2017
Primary completion
Jun 13, 2018
Study completion Jun 13, 2018
Sponsor
- Lead sponsor
- InotremIndustry
- Sponsor type
- Industry
- First posted
- May 18, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomised, double-blind, two-stage, placebo controlled study. It is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of nangibotide versus placebo in adult patients with septic shock.
Conditions
- Shock, Septic
Interventions
Nangibotide 0.3 mg/kgDrug
Formulated LR12 peptide
PlaceboDrug
placebo
Nangibotide 1 mg/kgDrug
Formulated LR12 peptide
Nangibotide 3 mg/kgDrug
Formulated LR12 peptide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients Experiencing Treatment Emergent Adverse Events From Screening Until Study CompletionTime frame: Adverse events experienced until D28 (End of study visit)
- Systolic Blood Pressure (SBP)Time frame: Vital signs were assessed each day from day zero (D0 [before investigational medicinal product initiation]) to end of infusion at day 5 (D5) and on final study day at day 28 (D28).
- Diastolic Blood Pressure (DBP)Time frame: Vital signs were assessed each day from day zero (D0 [before investigational medicinal product initiation]) to end of infusion at day 5 (D5) and on final study day at day 28 (D28).
- Median Arterial Pressure (MAP)Time frame: Vital signs were assessed each day from day zero (D0 [before investigational medicinal product initiation]) to end of infusion at day 5 (D5) and on final study day at day 28 (D28).
- Heart RateTime frame: Vital signs were assessed each day from day zero (D0 [before investigational medicinal product initiation]) to end of infusion at day 5 (D5).
- TemperatureTime frame: Vital signs were assessed each day from day zero (D0 [before investigational medicinal product initiation]) to end of infusion at day 5 (D5).
- ElectrocardiogramTime frame: Electrocardiogram was performed each day from D0 (before IMP initiation) to D5 (EOI) and on D28 (EOS).
- Anti-Drug Antibodies (ADA Dimer)Time frame: Anti-Drug Antibodies test were done at D0, D10 and D28 in all patients.
- Anti-Drug Antibodies (ADA Monomer)Time frame: Anti-Drug Antibodies test were measured at D0, D10 and D28.
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Cliniques Universitaires Saint-Luc (there may be other sites in this country)
Brussels, Belgium
Inserm Clinical Investigational Center, CHU Dupuytren (there may be other sites in this country)
Limoges, France
Radboudumc (there may be other sites in this country)
Nijmegen, Netherlands
Hospital Clínico San Carlos, Medicina Intensiva (there may be other sites in this country)
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.